DUBLIN–(BUSINESS WIRE)–The “Acute Bacterial Skin and Skin Structure Infections – Pipeline Insight, 2021” clinical trials has been added to ResearchAndMarkets.com’s offering.
This Acute Bacterial Skin and Skin Structure Infections – Pipeline Insight, 2021 provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Acute Bacterial Skin and Skin Structure Infections pipeline landscape.
It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Acute Bacterial Skin and Skin Structure Infections R&D. The therapies under development are focused on novel approaches to treat/improve Acute Bacterial Skin and Skin Structure Infections.
Acute Bacterial Skin and Skin Structure Infections Emerging Drugs Chapters
This segment of the Acute Bacterial Skin and Skin Structure Infections report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Acute Bacterial Skin and Skin Structure Infections Emerging Drugs
Zevtera: Basilea Pharmaceutica
Zevtera (Ceftobiprole medocaril), the prodrug of the active moiety ceftobiprole, is a cephalosporin antibiotic for intravenous administration with rapid bactericidal activity against a wide range of Gram-positive and Gram-negative bacteria. This includes methicillin-susceptible and resistant Staphylococcus aureus (MSSA, MRSA) and susceptible Pseudomonas spp. The drug is approved and marketed as Zevtera and Mabelio in a number of countries in Europe and beyond.
Basilea has entered into license and distribution agreements for the brand in Europe, Latin America, China, Canada, Israel, and the Middle East and North Africa (MENA) regions. The drug is currently in Phase III stage of clinical trial evaluation to treat Acute Bacterial Skin and Skin Structure Infections.
Contezolid acefosamil: MicuRx Pharmaceuticals
Contezolid is an oral oxazolidinone antibiotic designed to treat drug-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE), while offering physicians and patients a new therapeutic option than currently available oxazolidinone agents. The development of contezolid in China has been designated as a “Significant New Drugs Development Special Project”, and contezolid has also been granted QIDP designation and Fast Track status by the US FDA.
Major Players in Acute Bacterial Skin and Skin Structure Infections
There are approx. 15+ key companies which are developing the therapies for Acute Bacterial Skin and Skin Structure Infections. The companies which have their Acute Bacterial Skin and Skin Structure Infections drug candidates in the most advanced stage, i.e. phase III include, Basilea Pharmaceutica.
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Acute Bacterial Skin and Skin Structure Infections drugs?
- How many Acute Bacterial Skin and Skin Structure Infections drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Acute Bacterial Skin and Skin Structure Infections?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Acute Bacterial Skin and Skin Structure Infections therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Acute Bacterial Skin and Skin Structure Infections and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Basilea Pharmaceutica
- MicuRx Pharmaceuticals
- TenNor Therapeutics Limited
- GlaxoSmithKline
- Debiopharm Group
- Innovation Pharmaceuticals, Inc.
- Botanix pharmaceuticals
- Taxis Pharmaceuticals
Key Products
- Zevtera
- Contezolid acefosamil
- TNP-2092
- GSK2140944
- Debio 1452
- Brilacidin
- TXA709
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/5bagk
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900